TICKERNERD
Menu
NMRANMRAHealthcare · Biotechnology

NMRA Stock Forecast: Neumora Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.48
+2.52% on the day

The 9 Wall Street analysts covering Neumora Therapeutics, Inc. hold a median 12-month price target of $5 — +942.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$88.5M
Ticker Nerd rank
30 / 100
Median analyst target
$5.00
Analysts covering
9
Revenue$0.0
Operating income−$42.2M
Net income−$43.1M
Free cash flow−$39.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.8%
1M
−61.6%
YTD
−73.2%
1Y
−75.3%
From 52W high
−86.6%
From 52W low
+2.5%
$0.47
$3.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NMRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neumora Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
84
Accruals
83
Size
76
Revisions
50
Momentum
21
Value
17
Quality
16
Volatility
15
Issuance
10

Growth (84): Sales and profits are climbing, and climbing faster than before.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NMRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NMRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26NMRAHigh $14.00Median $5.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7 Buy1 Hold1 Sell
Low $3.00Median $5.00High $14.00

The green dot is the last close — the median target sits +942.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026RBC CapitalMaintainsOutperform$7.00 → $5.00
18 June 2026MizuhoMaintainsOutperform—
16 June 2026HC Wainwright & Co.MaintainsBuy—
16 June 2026NeedhamMaintainsBuy—
31 Mar 2026GuggenheimReiteratesBuy—
31 Mar 2026NeedhamReiteratesBuy—
17 Feb 2026William BlairUpgradeOutperform—
12 Jan 2026Leerink PartnersInitiatesOutperform—
1 Dec 2025RBC CapitalUpgradeOutperform—
17 Nov 2025StifelMaintainsHold—
28 Oct 2025NeedhamMaintainsBuy—
27 Oct 2025GuggenheimUpgradeBuy—
16 Sept 2025JP MorganDowngradeUnderweight—
16 July 2025MizuhoMaintainsOutperform—
13 May 2025NeedhamReiteratesBuy—
10 Apr 2025NeedhamReiteratesBuy—
2 Apr 2025B of A SecuritiesDowngradeUnderperform—
10 Mar 2025GuggenheimDowngradeNeutral—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025StifelDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NMRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NMRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Neumora Therapeutics, Inc. returned −75.3% against +16.2% for the S&P 500, dividends included.

NMRA vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26NMRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NMRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
2
Fundamentals

Neumora Therapeutics, Inc. (NMRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
2.0×

Cheaper than 44% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−187.1%

Higher than 8% of US stocks

Return on assets
−73.9%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neumora Therapeutics, Inc. (NMRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neumora Therapeutics, Inc. has a market value of $88.5M and an enterprise value of $24.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$212.7M.

  • Diluted earnings per share, trailing twelve months: $−1.23.

  • Free cash flow in the twelve months to 30 June 2026: −$180.5M.

  • Shares outstanding: 185.3M.

  • Trailing P/E: −0.3×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neumora Therapeutics, Inc. employs 63 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

NMRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NMRANeumora Therapeutics, Inc.$88.5M
30
ICCCImmuCell Corp.$88.2M
93
MISTMilestone Pharmaceuticals, Inc.$88.7M
16
CGTXCognition Therapeutics, Inc.$85.1M
35
RLYBRallybio Corp.$89.7M
55
TELOTelomir Pharmaceuticals, Inc.$84.7M
28
NRXSNeurAxis, Inc.$83.8M
58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neumora Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NMRA news & analysis

Biotech Options Buzz: UTHR, NMRA, EWTX

Schaeffers Research · 18 Sept 2026neutral

Biotech stocks, including Neumora Therapeutics (NMRA), are dominating today's unusual options volume list alongside United Therapeutics and Edgewise Therapeutics. The companies are attracting outsized attention in the options pits, according to Schaeffers Research.

Why it matters — The unusual options activity in NMRA signals heightened investor attention and trading interest in the company that day, which NMRA watchers would want to note.

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026positive

Neumora Therapeutics reported its second quarter 2026 financial results and provided a business update. The company announced favorable pre-clinical data for NMRA-215, with plans to submit an Investigational New Drug application in the fourth quarter of 2026 and initiate a Phase 1 study by the end of 2026.

Why it matters — The favorable pre-clinical data and expected progression of NMRA-215 toward clinical trials signal a near-term catalyst for Neumora's pipeline for investors tracking the company.

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

GlobeNewsWire · 27 July 2026positive

Neumora Therapeutics reported favorable toxicology results for NMRA-215 and plans to submit an Investigational New Drug application in the fourth quarter of 2026, with a Phase 1 study expected to start by the end of that year.

Why it matters — The favorable toxicology results and clear timeline for IND submission and Phase 1 initiation signal that NMRA-215 is progressing toward clinical development, a key milestone for the company's pipeline.

FAQ

Frequently asked questions about NMRA stock

What is the NMRA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Neumora Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $3 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NMRA stock a buy right now?

Of the 9 analysts covering Neumora Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Neumora Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NMRA?

As at 8 Oct 2026, Neumora Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).

Will NMRA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +942.1% from the last close, and Ticker Nerd's factor model ranks Neumora Therapeutics, Inc. 30 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NMRA stock forecast for 2030?

No analyst covering Neumora Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NMRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $14 over the next 12 months.

How has NMRA stock performed over the past year?

Neumora Therapeutics, Inc. returned -75.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neumora Therapeutics, Inc. do?

Neumora Therapeutics, Inc. Common Stock represents Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions.

What is the latest news on NMRA?

The most recent item we track (Schaeffers Research, 18 Sept 2026): "Biotech Options Buzz: UTHR, NMRA, EWTX". Biotech stocks, including Neumora Therapeutics (NMRA), are dominating today's unusual options volume list alongside United Therapeutics and Edgewise Therapeutics. The companies are attracting outsized attention in the options pits, according to Schaeffers Research.

Company

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. Common Stock represents Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. The company applies a precision medicine approach that combines neuroscience, biological insight, and data science to identify and advance therapies aimed at central nervous system targets. Its current pipeline includes candidate medicines in clinical and preclinical development for major depressive disorder, agitation associated with dementia, schizophrenia, Parkinson’s disease, ALS, and obesity-related metabolic disease. Neumora Therapeutics is positioned within the biotechnology sector as a research-driven company centered on novel mechanisms of action for underserved neurological and psychiatric disorders. The common stock reflects the market’s view of a company whose value is tied to progress across this specialized drug development pipeline and the broader demand for new CNS therapies.

CEO Dr. Joshua Pinto Ph.D. · 63 employees · United States · https://www.neumoratx.com